Spruce Biosciences, Inc. (SPRB)
60.78
-2.52
(-3.98%)
USD |
NASDAQ |
Aug 28, 16:00
60.60
-0.18
(-0.30%)
After-Hours: 20:00
Spruce Biosciences Cash from Operations (Quarterly) : -22.12M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.12M |
| March 31, 2026 | -8.732M |
| December 31, 2025 | -6.456M |
| September 30, 2025 | -5.316M |
| June 30, 2025 | -8.828M |
| March 31, 2025 | -12.73M |
| December 31, 2024 | -20.68M |
| September 30, 2024 | -9.223M |
| June 30, 2024 | -11.11M |
| March 31, 2024 | -14.96M |
| December 31, 2023 | -11.21M |
| September 30, 2023 | -12.27M |
| June 30, 2023 | 1.993M |
| March 31, 2023 | -11.79M |
| Date | Value |
|---|---|
| December 31, 2022 | -11.74M |
| September 30, 2022 | -8.578M |
| June 30, 2022 | -9.541M |
| March 31, 2022 | -11.83M |
| December 31, 2021 | -9.799M |
| September 30, 2021 | -7.597M |
| June 30, 2021 | -9.694M |
| March 31, 2021 | -8.787M |
| December 31, 2020 | -9.266M |
| September 30, 2020 | -7.497M |
| June 30, 2020 | -4.80M |
| March 31, 2020 | -5.956M |
| December 31, 2019 | -2.907M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Biogen, Inc. | 448.90M |
| PTC Therapeutics, Inc. | 129.11M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.135M |
| Cash from Financing (Quarterly) | 64.47M |
| Free Cash Flow | -42.77M |
| Free Cash Flow Per Share (Quarterly) | -9.154 |
| Free Cash Flow to Equity (Quarterly) | -22.80M |
| Free Cash Flow to Firm (Quarterly) | -21.16M |
| Free Cash Flow Yield | -49.05% |